Research
Switching from IV to SC vedolizumab in IBD: real-world effectiveness and safety over 48 weeks
Nature ·
The Brief
- A real-world study reports effectiveness and safety over 48 weeks after patients with IBD switched from IV to subcutaneous vedolizumab.
- The article is titled "Switching from IV to SC vedolizumab in IBD: real-world effectiveness and safety over 48 weeks" and appeared in the Nature subject feed on 2026-11-17.
- The source provided contains no summary, so specific results are not available here.
Why it matters
For clinicians and patients, the study addresses whether moving from intravenous to subcutaneous vedolizumab keeps treatment effective and safe in everyday practice, not only in trials.
Who’s affected
- patients with inflammatory bowel disease
- gastroenterologists and clinicians treating IBD
- #vedolizumab
- #inflammatory bowel disease
- #subcutaneous drug delivery
- #real-world evidence
- #ibd treatment